RxDoctor Payments DataLook up a doctor →

Jason Berner, MD

Endocrinology, Diabetes & Metabolism · Jasper, GANPI 1144201781

Payments from drug & device makers

$2,612,711in general payments, 2019–2025

Across 2,254 payments — averaging $1159.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$412K
  • Merck$404K
  • AbbVie$312K
  • Lilly USA, LLC$292K
  • Eli Lilly$253K
  • Insulet Corporation$219K
  • plus $720K from 54 others
$27,787in research payments, 2019–2025

Across 15 payments — averaging $1852.46 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$27K
  • AbbVie$1K

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Medtronic(2 entities)58$411,739
Merck32$404,134
AbbVie52$312,103
Lilly USA, LLC620$291,789
Eli Lilly9$253,430
Insulet Corporation38$219,023
Alnylam Pharmaceuticals Inc.292$215,208
Novartis9$111,225
AstraZeneca(2 entities)92$72,111
Biogen2$66,067
Amgen(2 entities)42$57,822
Astrazeneca UK Limited1$35,310
Bayer27$34,951
Amarin Pharma, Inc.94$32,626
Boehringer Ingelheim114$27,140
Dexcom, Inc.40$22,759
Abbott88$22,149
Sanofi-aventis U.S. LLC85$4,719
Johnson & Johnson10$2,569
Ascendis Pharma Endocrinology Inc16$2,439
Novo Nordisk187$2,125
IBSA Pharma Inc.12$2,094
Amneal Pharmaceuticals LLC25$1,737
Corcept Therapeutics49$1,322
Mannkind Corporation44$906
Xeris Pharmaceuticals, Inc.32$806
Bigfoot Biomedical Inc13$610
Antares Pharma, Inc.28$476
Tandem Diabetes Care, Inc.16$447
Cequr Corporation5$326
Valeritas, Inc.12$286
Zealand Pharma US, Inc.15$238
Metuchen Pharmaceuticals1$167
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC11$158
Kyowa Kirin, Inc.7$139
Pfizer8$137
Intuity Medical Inc6$128
Esperion Therapeutics, Inc.8$127
Astellas Pharma US Inc1$99
Madrigal Pharmaceuticals3$92
BETA Bionics, Inc.4$89
Takeda Pharmaceuticals U.S.A., Inc.4$78
Verity Pharmaceuticals Inc.3$78
Sequel Med Tech, LLC3$65
Ultragenyx Pharmaceutical Inc.3$64
Embecta Corp.3$63
Neurocrine Biosciences, Inc.2$62
Recordati_rare_diseases_inc.3$48
Endo Pharmaceuticals Inc.3$47
Senseonics, Incorporated3$44
Radius Health, Inc.2$42
Shire North American Group Inc2$41
Halozyme Inc2$39
Averitas Pharma Inc.1$28
Tolmar, Inc.1$20
Eisai Inc.1$20
Ascensia Diabetes Care US Inc.1$19
Organon1$18
Kowa Pharmaceuticals America, Inc.1$17
Roche Diabetes Care, Inc.1$17

How this compares

$2,612,711 in reported general payments places this provider in the 95th percentile of 222 endocrinology, diabetes & metabolism providers in Georgia.

See all endocrinology, diabetes & metabolism providers in Georgia →

Medicare billing

Part B allowed, 2024
$131,034
Medicare patients
400
Services billed
2,217

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other endocrinology, diabetes & metabolism in Jasper

See the full list for Georgia →

Where these figures come from

Is this you, or does something look wrong? →